Literature DB >> 25303230

Prognostic value of long non-coding RNA HOTAIR in various cancers.

Qiwen Deng1, Huiling Sun2, Bangshun He1, Yuqin Pan1, Tianyi Gao3, Jie Chen2, Houqun Ying4, Xian Liu1, Feng Wang1, Yong Xu1, Shukui Wang1.   

Abstract

Long non-coding RNA has been involved in cancer progression, and high HOX transcript antisense intergenic RNA (HOTAIR) is thought to be a poor prognostic indicator in tumorigenesis of multiple types of cancer. Hence, the present study further reveals its prognostic value in tumor malignancy. A systematic review of PubMed and Web of Science was carried out to select literatures relevant to the correlation between HOTAIR expression levels and clinical outcome of various tumors. Overall survival (OS), metastasis-free survival (MFS), recurrence-free survival (RFS), and disease-free survival (DFS) were subsequently analyzed. Data from studies directly reporting a hazard ratio (HR) and the corresponding 95% confidence interval (CI) or a P value as well as survival curves were pooled in the current meta-analysis. A total of 2255 patients from 19 literatures almost published in 2011 or later were included in the analysis. The results suggest that HOTAIR was highly associated with HR for OS of 2.33 (95%CI = 1.77-3.09, Pheterogeneity = 0.016). Stratified analyses indicate that elevated levels of HOTAIR appears to be a powerful prognostic biomarker for patients with colorectal cancer (HR = 3.02, 95CI% = 1.84-4.95, Pheterogeneity = 0.699) and esophageal squamous cell carcinomas (HR = 2.24, 95CI% = 1.67-3.01, Pheterogeneity = 0.711), a similar effect was also observed in analysis method and specimen, except for ethnicity. In addition, Hazard ratios for up-regulation of HOTAIR for MFS, RFS, and DFS were 2.32 (P<0.001), 1.98 (P = 0.369), and 3.29 (P = 0.001), respectively. In summary, the high level of HOTAIR is intimately associated with an adverse OS in numerous cancers, suggesting that HOTAIR may act as a potential biomarker for the development of malignancies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25303230      PMCID: PMC4193855          DOI: 10.1371/journal.pone.0110059

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Noncoding RNAs (ncRNA) are initially identified from sequencing and microarray for whole genome and transcriptome, and at least 90% of ncRNAs has been found to be actively transcribed [1], [2]. The transcription of ncRNA revealed its complication in biogenesis than protein-coding RNA, such as extensive antisense, overlapping and non-coding RNA expression [3], [4], [5]. Despite initial argument claimed that ncRNA may be a fake transcriptional noise, increasing evidences suggested that ncRNAs may play a dominant biological role in cell metabolism and survival [6], [7], [8], [9]. Furthermore, the recent studies demonstrated that long non-coding RNAs (lncRNA, 200nt in length) express at tissue-specific patterns and that it is abnormally regulated in a variety of diseases, including cancer [10], [11], [12], [13]. Multiple regulatory bases have been involved in the regulation of lncRNA, such as transcriptional regulation, epigenetic regulation, and posttranscriptional regulation [9], [14]. Moreover, lncRNAs exhibit unique profiles in many kinds of cancers, which represent carcinogenesis and progression regarded as a predictor of patient outcomes [15], [16], [17]. HOTAIR, a prominently focused lncRNA, was initially reported to be implicated in primary breast cancer and breast cancer metastasis, wherein elevated HOTAIR promoted tumor invasiveness and metastasis [18]. HOTAIR overexpression has been shown to be associated with expression of polycomb repressive complex 2 (PRC2), inducing its relating methylation of histone H3 lysine 27 (H3K27) [10], [18]. In addition to breast cancer [18], recent clinical evidences show HOTAIR is also involved in the progression of many other types of cancer, such as hepatocellular carcinomas (HCC) [19], colorectal cancer (CRC) [20], esophageal squamous cell carcinomas (ESCC) [21], suggesting that HOTAIR expression serves as a prognostic factor for tumorigenesis. Although HOTAIR expression is considered to relating to clinical prognosis of multiple cancers, the impact of HOTAIR on the development of cancer still remains elusive. Some studies reported that up-regulation of HOTAIR contributes to tumorigenesis, including bladder cancer [22], cervical cancer [23], colorectal cancer [24], etc., while a few evidences exhibited an adverse effect recognized as a protective factor to against carcinogenesis [25]. It is necessary therefore to clarify the relationship between HOTAIR and cancer. Thus, the present study conducted the first meta-analysis using qualified relevant literatures to achieve a precise evaluation of the association between HOTAIR expression and cancer clinical prognosis.

Materials and Methods

Data sources and searches

The published data searching was performed using a literature review system with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines [26]. The selected literatures were determined via an electronic search of PubMed and Web of Science using these following terms: “HOTAIR”, “cancer or tumor or carcinomas” and “prognosis or outcome”. The last search was updated in July 18, 2014. Citation lists of retrieved articles were searched manually to ensure sensitivity of the search strategy.

Study selection

Studies considered eligible met the following criteria: 1) studied patients with any type of cancers; 2) explored the link between HOTAIR and clinical prognosis; 3) availability of a hazard ratio (HR) and 95% confidence interval (CI) or a P value for overall survival (OS). For a secondary analysis, studies including an HR for metastasis-free survival (MFS), disease-free survival (DFS), or recurrence-free survival (RFS) were also used to further analyze. OS [27], MFS [28], DFS [27], and RFS [29] were described previously; 4) published as a full paper in English. Studies were excluded based on the following criteria: 1) duplicated studies, reviews, letters, unpublished data, and comments; 2) those published in language other than English; 3) lack of key information for further analysis; 4) non-human research.

Data extraction

Two investigators (QWD, HLS) independently evaluated and extracted data from each identified studies based on criteria of inclusion and exclusion. Corresponding authors were contacted to clarify missing or ambiguous data. OS was treated as a dominant outcome of interest, but MFS, RFS and DFS were set as the secondary outcomes. The following information was carefully extracted: name of first author, year of publication, country of origin, ethnicity of the study population, type of specimen, cancer type, number of patients included in analysis, detection method of HOTAIR, cut-off defining high HOTAIR, follow-up period, and HR and corresponding 95% CI for OS, MFS, RFS, or DFS as applicable. Cancer type subgroups were generated for the main outcome if at least two studies on the type of cancer were available; the only one study was pooled in a subgroup termed “Other.” HR was firstly extracted from multivariable analysis where available. Otherwise, HR was extracted from univariate analysis, and calculated from Kaplan-Meier survival curve by HR digitizer software Engauge 4.0 as described previously [30].

Statistical analyses

All extracted data were combined into a meta-analysis using STATA software version 11.0 (STATA Corporation, College Station, TX, USA). Hazard ratios with the corresponding 95% CIs were used to estimate the strength of the link between HOTAIR and clinical prognosis. If HR was not directly reported, a mathematical estimation was conducted by calculating the necessary data on the basis of the previously reported methods [31]. Cochran's Q test and Higgins I-squared statistic were used to estimate the heterogeneity of pooled results. If P <0.05 for Q-test showed significant heterogeneity among studies, the random-effects model (DerSimoian-Laird method) was implemented to calculate the pooled HRs [32]. Otherwise, the fixed-effects model (Mantel-Haenszel method) was used [33]. To further explore the potential source of heterogeneity among studies, meta-regression was performed utilizing variables as cancer type, ethnicity, analysis method, type of specimen. To validate the stability of outcomes in this meta-analysis, sensitivity analysis was performed by sequential omission of each individual study. Publication bias was conducted by Begg's funnel plot and Egger's linear regression test and a P <0.05 was considered representative of statistically significant publication bias.

Results

Characteristics of studies

There were 71 papers in the electronic search of PubMed and EMBASE. On the basis of the inclusion criteria, 19 eligible papers were enrolled in this meta-analysis (shown in Figure 1). The main characteristics of included studies are shown in Table 1; all studies were almost published in 2011 or later. There were 16 studies for OS, 3 for MFS, 3 for RFS, and 2 for DFS in the meta-analysis. Participants in 16 studies were Asian and in the other 3 studies were Caucasian. Various cancers were recorded in our study, including BC, HCC, CRC, ESCC, etc. The types of specimen were tissue for twenty-two studies and blood for one study. The cut-off values included in the studies were inconsistent due to different detection methods, even in 6 studies were not reported. Hazard ratios with the corresponding 95% CIs were extracted from univariate analysis and the graphical survival plots in 6 studies, and multivariate analysis in 18 studies.
Figure 1

Flow chart for selection of studies for inclusion in this meta-analysis.

Table 1

Main characteristics of included studies.

First authorYearCountryEthnicitySpecimensCancer typeMethodCut-off* Follow-up (month)NumberAnalysisSurvival
Yang [19] 2011ChinaAsianTissueHCCRT-qPCRNR18.6 (median)60MultivariableRFS
Kogo [20] 2011JapanAsianTissueCRCRT-qPCR0.02736 (mean)100MultivariableOS
Lu [40] 2012ItalyCaucasianTissueBCRT-qPCRNR86 (median)336MultivariableOS, RFS
Li [41] 2012ChinaAsianTissueLSCCRT-qPCRNR60 (total)72MultivariableOS
Nie [42] 2013ChinaAsianTissueNPCISH669 (median)160MultivariableOS
Nakagawa [43] 2013JapanAsianTissueNSCLCRT-qPCR231.4 (median)77UnivariableDFS
Lv [44] 2013ChinaAsianTissueESCCISH660 (total)93UnivariableOS
Li [45] 2013ChinaAsianTissueESCCRT-qPCR12560 (total)100MultivariableOS
Ge [46] 2013ChinaAsianTissueESCCRT-qPCRNR60 (total)137MultivariableOS, MFS
Liu [47] 2013ChinaAsianTissueNSCLCRT-qPCR8.5760 (total)42UnivariableOS
Chen [48] 2013ChinaAsianTissueESCCRT-qPCR26.638 (mean)78MultivariableOS
Zhang [49] 2013ChinaAsianTissueGBMGSEANR50 (totoal)89MultivariableOS
Sørensen [50] 2013DenmarkCaucasianTissueBCMicroarray0.6217.2 (mean)164MultivariableMFS
Svoboda [51] 2014CzechCaucasianTissue, BloodCRCRT-qPCR0.7, 4.435 (mean)73, 84MultivariableOS
Qiu [52] 2014ChinaAsianTissueEOCRT-qPCRNR50.5 (median)64UnivariableOS, DFS
Huang [53] 2014ChinaAsianTissueCervicalRT-qPCRNR42 (mean)218MultivariableOS
Liu [54] 2014ChinaAsianTissueGCRT-qPCRNR50 (totoal)78UnivariableOS
Wu [55] 2014ChinaAsianTissueCRCRT-qPCR555.5 (median)120MultivariableOS, MFS
Yan [29] 2014ChinaAsianTissueBladderRT-qPCRNR60 (total)110MultivariableRFS

*cancerous/noncancerous

HCC, hepatocellular carcinoma; CRC, colorectal cancer; BC, breast cancer; LSCC, laryngeal squamous cell carcinoma; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; ESCC, esophageal squamous cell carcinoma; GBM, glioblastoma multiforme; EOC, epithelial ovarian cancer; GC, gastric cancer; RT-qPCR, real-time quantitative PCR; ISH, in situ hybridization; GSEA, gene set enrichment analysis; NR, not reported; OS, overall survival; MFS, metastasis-free survival; RFS, recurrence-free survival; DFS, disease-free survival.

*cancerous/noncancerous HCC, hepatocellular carcinoma; CRC, colorectal cancer; BC, breast cancer; LSCC, laryngeal squamous cell carcinoma; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer; ESCC, esophageal squamous cell carcinoma; GBM, glioblastoma multiforme; EOC, epithelial ovarian cancer; GC, gastric cancer; RT-qPCR, real-time quantitative PCR; ISH, in situ hybridization; GSEA, gene set enrichment analysis; NR, not reported; OS, overall survival; MFS, metastasis-free survival; RFS, recurrence-free survival; DFS, disease-free survival.

Overall survival

The main results of this meta-analysis are shown in Table 2. 16 studies comprising 1844 patients reported HR for OS. It is suggested that elevated HOTAIR predicted a poor outcome for OS (HR = 2.33, 95%CI  = 1.77-3.09, P H = 0.016; Figure 2). Stratified analyses by cancer type indicated that the prognostic effect of HOTAIR was highest in CRC (HR = 3.02, 95%CI = 1.84-4.95, P H = 0.699), followed by ESCC (HR = 2.24, 95%CI = 1.67-3.01, P H = 0.016). HR for the subgroup of other cancers was 2.18 (95%CI = 1.25-3.78, P H =  0.001).
Table 2

The main results of pooled analyses.

SurvivalVariablesNO. of studiesNO. of patients P valueRegression model
P H P Z P E RandomFixed
OSAll1618440.0160.0000.110 2.34 (1.77–3.09) 2.20 (1.82–2.66)
Cancer type
CRC43770.6990.0003.02 (1.84–4.95) 3.02 (1.84–4.95)
ESCC44080.7110.0002.24 (1.67–3.01) 2.24 (1.67–3.01)
Other810590.0010.006 2.18 (1.25–3.78) 1.95 (1.46–2.60)
Ethnicity
Asian1313510.8940.0002.43 (1.99–2.97) 2.43 (1.99–2.97)
Caucasian34930.0010.482 1.92 (0.31–11.91) 0.92 (0.51–1.67)
Analysis method
Univariable42770.3290.0002.53 (1.64–3.89) 2.13 (1.71–2.65)
Multivarible1215670.0090.000 2.26 (1.59–3.20) 2.44 (1.67–3.55)
Specimen
Tissue1517600.0150.000 2.29 (1.72–3.04) 2.17 (1.79–2.63)
Blood1840.0374.96 (1.10–22.37) 4.96 (1.10–22.37)
MFSAll34210.0800.0002.81 (1.44–5.57) 2.32 (1.62–3.33)
RFSAll35060.0000.369 1.98 (0.44–8.85) 1.96 (1.37–2.81)
DFSAll21410.9690.0013.29 (1.61–6.70) 3.29 (1.61–6.70)

P H, P value of heterogeneity test; P Z, P value of Z test; P E, P value of Egger's test; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; OS, overall survival; MFS, metastasis-free survival; RFS, recurrence-free survival; DFS, disease-free survival.

Italic indicates HR with 95% CI used to analyses.

The bold represents statistically significant results.

Figure 2

Forest plots of studies evaluating hazard ratios (HRs) of HOTAIR for overall survival.

P H, P value of heterogeneity test; P Z, P value of Z test; P E, P value of Egger's test; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; OS, overall survival; MFS, metastasis-free survival; RFS, recurrence-free survival; DFS, disease-free survival. Italic indicates HR with 95% CI used to analyses. The bold represents statistically significant results. The effect of elevated HOTAIR on OS among different races is shown in Table 2. The hazard ratios were 2.43 (95%CI = 1.99-2.97, P H =  0.894) for Asian, and 1.92 (95%CI = 0.31-11.91, P H =  0.001) for Caucasian. When different analysis methods were considered, HOTAIR was a strong prognostic marker both by univariate analysis (HR =  2.13, 95%CI = 1.71-2.65, P H = 0.329) and by multivariate analysis (HR = 2.26, 95%CI = 1.59-3.20, P H = 0.009). Performing subgroup analyses stratified by specimen, increased HOTAIR was closely associated with poor prognosis both in tissue (HR = 2.29, 95%CI = 1.72-3.04, P H = 0.015) and in blood (HR = 4.96, 95%CI = 1.10-22.37). Sensitivity analysis is presented in Figure 3. The result pattern was not significantly impacted by removing single study each time. Begg's funnel plot and the Egger's linear regression test were conducted to evaluate publication bias. The shape of the funnel plot showed no significant asymmetry in Figure 4. Subsequently, Egger's test also suggested no evidence of publication bias (P = 0.110).
Figure 3

Sensitivity analysis of effect of individual studies on the pooled HRs for HOTAIR and overall survival of patients.

Figure 4

Funnel plot of HR for overall survival for high HOTAIR (vertical axis) and the standard error (SE) for HR (horizontal axis).

Each study represented by one circle. The horizontal line represented the pooled effect estimate.

Funnel plot of HR for overall survival for high HOTAIR (vertical axis) and the standard error (SE) for HR (horizontal axis).

Each study represented by one circle. The horizontal line represented the pooled effect estimate.

Metastasis-free survival, recurrence-free survival and disease-free survival

Three studies comprising 421 patients reported HRs for MFS. Overall, HOTAIR greater than the cut-off was associated with an HR for MFS of 2.32 (95%CI = 1.62-3.33, P H = 0.080). Three studies comprising 506 patients showed HRs for RFS. HOTAIR was not linked with poor RFS. Two studies comprising 141 patients reported HRs for DFS. Up-regulation of HOTAIR predicted a poor clinical outcome for DFS (HR = 3.29, 95%CI = 1.61-6.70, P H = 0.969).

Discussion

As a novel molecular basis, the study of lncRNA has focused on the impact of lncRNA on cancer pathogenesis and prognosis, providing a new insight into cancer therapeutic strategy [34], [35]. Despite substantial progress of lncRNAs in cancer nosogenesis and prognosis, the prognostic effect of lncRNAs is still confused. To explore the prognostic impact of lncRNAs in cancer, this system review and meta-analysis was performed to investigate the impact of HOTAIR on tumor prognosis for achieving more consistent and precise conclusion. Here we undertook meta-analysis of 18 literatures comprising 2255 patients with tumors to assess the prognostic effect of HOTAIR. We found that an accordant effect of an elevated HOTAIR on OS (HR = 2.33) with the similar hazard ratios among various cancer type subgroups and across analytical methods, or specimens, except for ethnicity subgroups. HOTAIR has been shown to contribute to the progression of many types of cancer and is nowadays considered as a hallmark of cancer [36]. The strong impact on OS was highest in CRC, which is further supported by evidences that HOTAIR plays a critical role in the carcinogenesis of CRC as a result of promoted multipotent cell differentiation [20]. In particular, the elevated levels of HOTAIR are highly associated with worse OS in Asian, but not in Caucasian, suggesting that interaction between genetic and environmental factors may contribute to cancer development. In addition, clinicopathological features and drug treatment status could modify the effect of HOTAIR [25]. However, a study reported that HOTAIR induces repressive chromatin status by promoting the formation of H3K27, suggesting that HOTAIR may function as a tumor suppressor gene by inhibiting proliferation of cancer stem cells [18]. The present study further verify that the levels of HOTAIR is highly associated with cancer development, although the prognostic effect of HOTAIR on MFS and DFS is still remained for the future studies. Importantly, the results are consistent in the tested types of cancer regardless of different data resources and analysis methods. The mechanisms underlying the association between the high levels of HOTAIR and poor outcome of cancers are still unclear. This study may predict the following potential mechanisms involved in the prognostic impact of HOTAIR on carcinogenesis. HOTAIR regulates the chromatin methylation state by inducing genome-wide retargeting of PRC2 and promotes metastasis of breast cancer by silencing multiple metastasis-suppressing genes [18]. Consequently, PRC2 has been reported to be involved in stem cell pluripotency and progression ofEZH2, SUZ12, and EED [36], [37]. Consistently, HOTAIR knockdown not only suppressed cell invasion, but also decreased cell proliferation, altered cell cycle progression, and induced apoptosis [38]. Physicians prefer to use prognostic data when speaking to patients. As HOTAIR offers independent prognostic information, we may incorporate HOTAIR in a simple score to provide an appropriate therapeutic strategy. In recent years, a few clinical studies with cancer patients showed that reducing levels of HOTAIR is closely associated with a good response to treatment [39]. Furthermore, HOTAIR has been verified to be an independent prognostic indicator in CRC patients [24]. It was suggested that changing blood HOTAIR levels might be useful for tailoring of therapy for cancer patients. Some limitations in this study should be acknowledged. Firstly, only summarized data rather than individual patient data were used. Secondly, a part of studies, especially in subgroups analyses, was lightly relative. Thirdly, because some cut-off values were not reported and the criteria of calculating cut-off value were inconsistent, stratified analysis by cut-off values was not conducted to suggest whether cut-off values were the origin of heterogeneity. Fourthly, we only included studies reporting HR or survival curves, and consequently some publications reporting on the prognostic value of HOTAIR were excluded. For example, only odds ratios were reported, so the selection bias might be appeared. Finally, most of the included studies do not explicitly control for such concurrent conditions, and these may confound the measurement of HOTAIR. In summary, up-regulation of HOTAIR is associated with adverse survival in many types of cancer, and HOTAIR may serve as an effective prognostic biomarker for diagnosis of cancer. Therefore, clinical checking the levels of HOTAIR expression may provide a promising approach to identify patients who would require more intimately care for personally tailored medical inspection to monitor cancer prevention and treatment. Flow chart. (TIF) Click here for additional data file. Forest plots. (TIF) Click here for additional data file. Sensitivity analysis. (TIF) Click here for additional data file. Funnel plot. (TIF) Click here for additional data file. Main characteristics. (XLSX) Click here for additional data file.
  49 in total

Review 1.  Genome-wide transcription and the implications for genomic organization.

Authors:  Philipp Kapranov; Aarron T Willingham; Thomas R Gingeras
Journal:  Nat Rev Genet       Date:  2007-05-08       Impact factor: 53.242

2.  Long, abundantly expressed non-coding transcripts are altered in cancer.

Authors:  Damon S Perez; Tiffany R Hoage; Jay R Pritchett; Allison L Ducharme-Smith; Meredith L Halling; Sree C Ganapathiraju; Paul S Streng; David I Smith
Journal:  Hum Mol Genet       Date:  2007-11-15       Impact factor: 6.150

3.  Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer.

Authors:  Ze-Hua Wu; Xiao-Liang Wang; Hua-Mei Tang; Tao Jiang; Jian Chen; Su Lu; Guo-Qiang Qiu; Zhi-Hai Peng; Dong-Wang Yan
Journal:  Oncol Rep       Date:  2014-05-15       Impact factor: 3.906

4.  Correlation of MTDH/AEG-1 and HOTAIR Expression with Metastasis and Response to Treatment in Sarcoma Patients.

Authors:  Mohammed M Milhem; Tina Knutson; Shujie Yang; Danlin Zhu; Xinjun Wang; Kimberly K Leslie; Xiangbing Meng
Journal:  J Cancer Sci Ther       Date:  2011-12-29

5.  Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project.

Authors:  Ewan Birney; John A Stamatoyannopoulos; Anindya Dutta; Roderic Guigó; Thomas R Gingeras; Elliott H Margulies; Zhiping Weng; Michael Snyder; Emmanouil T Dermitzakis; Robert E Thurman; Michael S Kuehn; Christopher M Taylor; Shane Neph; Christoph M Koch; Saurabh Asthana; Ankit Malhotra; Ivan Adzhubei; Jason A Greenbaum; Robert M Andrews; Paul Flicek; Patrick J Boyle; Hua Cao; Nigel P Carter; Gayle K Clelland; Sean Davis; Nathan Day; Pawandeep Dhami; Shane C Dillon; Michael O Dorschner; Heike Fiegler; Paul G Giresi; Jeff Goldy; Michael Hawrylycz; Andrew Haydock; Richard Humbert; Keith D James; Brett E Johnson; Ericka M Johnson; Tristan T Frum; Elizabeth R Rosenzweig; Neerja Karnani; Kirsten Lee; Gregory C Lefebvre; Patrick A Navas; Fidencio Neri; Stephen C J Parker; Peter J Sabo; Richard Sandstrom; Anthony Shafer; David Vetrie; Molly Weaver; Sarah Wilcox; Man Yu; Francis S Collins; Job Dekker; Jason D Lieb; Thomas D Tullius; Gregory E Crawford; Shamil Sunyaev; William S Noble; Ian Dunham; France Denoeud; Alexandre Reymond; Philipp Kapranov; Joel Rozowsky; Deyou Zheng; Robert Castelo; Adam Frankish; Jennifer Harrow; Srinka Ghosh; Albin Sandelin; Ivo L Hofacker; Robert Baertsch; Damian Keefe; Sujit Dike; Jill Cheng; Heather A Hirsch; Edward A Sekinger; Julien Lagarde; Josep F Abril; Atif Shahab; Christoph Flamm; Claudia Fried; Jörg Hackermüller; Jana Hertel; Manja Lindemeyer; Kristin Missal; Andrea Tanzer; Stefan Washietl; Jan Korbel; Olof Emanuelsson; Jakob S Pedersen; Nancy Holroyd; Ruth Taylor; David Swarbreck; Nicholas Matthews; Mark C Dickson; Daryl J Thomas; Matthew T Weirauch; James Gilbert; Jorg Drenkow; Ian Bell; XiaoDong Zhao; K G Srinivasan; Wing-Kin Sung; Hong Sain Ooi; Kuo Ping Chiu; Sylvain Foissac; Tyler Alioto; Michael Brent; Lior Pachter; Michael L Tress; Alfonso Valencia; Siew Woh Choo; Chiou Yu Choo; Catherine Ucla; Caroline Manzano; Carine Wyss; Evelyn Cheung; Taane G Clark; James B Brown; Madhavan Ganesh; Sandeep Patel; Hari Tammana; Jacqueline Chrast; Charlotte N Henrichsen; Chikatoshi Kai; Jun Kawai; Ugrappa Nagalakshmi; Jiaqian Wu; Zheng Lian; Jin Lian; Peter Newburger; Xueqing Zhang; Peter Bickel; John S Mattick; Piero Carninci; Yoshihide Hayashizaki; Sherman Weissman; Tim Hubbard; Richard M Myers; Jane Rogers; Peter F Stadler; Todd M Lowe; Chia-Lin Wei; Yijun Ruan; Kevin Struhl; Mark Gerstein; Stylianos E Antonarakis; Yutao Fu; Eric D Green; Ulaş Karaöz; Adam Siepel; James Taylor; Laura A Liefer; Kris A Wetterstrand; Peter J Good; Elise A Feingold; Mark S Guyer; Gregory M Cooper; George Asimenos; Colin N Dewey; Minmei Hou; Sergey Nikolaev; Juan I Montoya-Burgos; Ari Löytynoja; Simon Whelan; Fabio Pardi; Tim Massingham; Haiyan Huang; Nancy R Zhang; Ian Holmes; James C Mullikin; Abel Ureta-Vidal; Benedict Paten; Michael Seringhaus; Deanna Church; Kate Rosenbloom; W James Kent; Eric A Stone; Serafim Batzoglou; Nick Goldman; Ross C Hardison; David Haussler; Webb Miller; Arend Sidow; Nathan D Trinklein; Zhengdong D Zhang; Leah Barrera; Rhona Stuart; David C King; Adam Ameur; Stefan Enroth; Mark C Bieda; Jonghwan Kim; Akshay A Bhinge; Nan Jiang; Jun Liu; Fei Yao; Vinsensius B Vega; Charlie W H Lee; Patrick Ng; Atif Shahab; Annie Yang; Zarmik Moqtaderi; Zhou Zhu; Xiaoqin Xu; Sharon Squazzo; Matthew J Oberley; David Inman; Michael A Singer; Todd A Richmond; Kyle J Munn; Alvaro Rada-Iglesias; Ola Wallerman; Jan Komorowski; Joanna C Fowler; Phillippe Couttet; Alexander W Bruce; Oliver M Dovey; Peter D Ellis; Cordelia F Langford; David A Nix; Ghia Euskirchen; Stephen Hartman; Alexander E Urban; Peter Kraus; Sara Van Calcar; Nate Heintzman; Tae Hoon Kim; Kun Wang; Chunxu Qu; Gary Hon; Rosa Luna; Christopher K Glass; M Geoff Rosenfeld; Shelley Force Aldred; Sara J Cooper; Anason Halees; Jane M Lin; Hennady P Shulha; Xiaoling Zhang; Mousheng Xu; Jaafar N S Haidar; Yong Yu; Yijun Ruan; Vishwanath R Iyer; Roland D Green; Claes Wadelius; Peggy J Farnham; Bing Ren; Rachel A Harte; Angie S Hinrichs; Heather Trumbower; Hiram Clawson; Jennifer Hillman-Jackson; Ann S Zweig; Kayla Smith; Archana Thakkapallayil; Galt Barber; Robert M Kuhn; Donna Karolchik; Lluis Armengol; Christine P Bird; Paul I W de Bakker; Andrew D Kern; Nuria Lopez-Bigas; Joel D Martin; Barbara E Stranger; Abigail Woodroffe; Eugene Davydov; Antigone Dimas; Eduardo Eyras; Ingileif B Hallgrímsdóttir; Julian Huppert; Michael C Zody; Gonçalo R Abecasis; Xavier Estivill; Gerard G Bouffard; Xiaobin Guan; Nancy F Hansen; Jacquelyn R Idol; Valerie V B Maduro; Baishali Maskeri; Jennifer C McDowell; Morgan Park; Pamela J Thomas; Alice C Young; Robert W Blakesley; Donna M Muzny; Erica Sodergren; David A Wheeler; Kim C Worley; Huaiyang Jiang; George M Weinstock; Richard A Gibbs; Tina Graves; Robert Fulton; Elaine R Mardis; Richard K Wilson; Michele Clamp; James Cuff; Sante Gnerre; David B Jaffe; Jean L Chang; Kerstin Lindblad-Toh; Eric S Lander; Maxim Koriabine; Mikhail Nefedov; Kazutoyo Osoegawa; Yuko Yoshinaga; Baoli Zhu; Pieter J de Jong
Journal:  Nature       Date:  2007-06-14       Impact factor: 49.962

6.  Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival.

Authors:  Yan Nie; Xiang Liu; Shaohua Qu; Erwei Song; Hua Zou; Chang Gong
Journal:  Cancer Sci       Date:  2013-01-30       Impact factor: 6.716

7.  The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis.

Authors:  Weimin Wang; Yansu Chen; Jianliang Deng; Jianping Zhou; Yan Zhou; Shouyu Wang; Jianwei Zhou
Journal:  Tumour Biol       Date:  2014-06-29

Review 8.  The functional role of long non-coding RNA in human carcinomas.

Authors:  Ewan A Gibb; Carolyn J Brown; Wan L Lam
Journal:  Mol Cancer       Date:  2011-04-13       Impact factor: 27.401

9.  Long noncoding RNA HOTAIR is a prognostic marker for esophageal squamous cell carcinoma progression and survival.

Authors:  Xiao-Bin Lv; Gui-Yong Lian; Hao-Ran Wang; Erwei Song; Herui Yao; Ming-Hui Wang
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

10.  Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer.

Authors:  Ming Sun; Fei-yan Jin; Rui Xia; Rong Kong; Jin-hai Li; Tong-peng Xu; Yan-wen Liu; Er-bao Zhang; Xiang-hua Liu; Wei De
Journal:  BMC Cancer       Date:  2014-05-06       Impact factor: 4.430

View more
  20 in total

1.  Prioritization of non-coding disease-causing variants and long non-coding RNAs in liver cancer.

Authors:  Hua Li; Zekun He; Yang Gu; Lin Fang; Xin Lv
Journal:  Oncol Lett       Date:  2016-09-14       Impact factor: 2.967

2.  LncRNA MALAT1 overexpression is an unfavorable prognostic factor in human cancer: evidence from a meta-analysis.

Authors:  Jun Zhang; Bingya Zhang; Tiejun Wang; Hongyong Wang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 3.  Long Noncoding RNAs and Human Liver Disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Annu Rev Pathol       Date:  2021-08-20       Impact factor: 32.350

Review 4.  Long noncoding RNAs are novel potential prognostic biomarkers for esophageal squamous cell carcinoma: an overview.

Authors:  Han-Yu Deng; Yun-Cang Wang; Peng-Zhi Ni; Yi-Dan Lin; Long-Qi Chen
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 5.  There and Back Again: Hox Clusters Use Both DNA Strands.

Authors:  Elena L Novikova; Milana A Kulakova
Journal:  J Dev Biol       Date:  2021-07-15

Review 6.  TUG1: a pivotal oncogenic long non-coding RNA of human cancers.

Authors:  Zheng Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2016-06-23       Impact factor: 6.831

7.  Prognostic role of HOTAIR in four estrogen-dependent malignant tumors: a meta-analysis.

Authors:  Jing Li; Wen Wen; Shu Zhao; Jingxuan Wang; Jingyu Chen; Yanrong Wang; Qingyuan Zhang
Journal:  Onco Targets Ther       Date:  2015-06-15       Impact factor: 4.147

Review 8.  Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma.

Authors:  Maximilian Seles; Georg C Hutterer; Tobias Kiesslich; Karl Pummer; Ioana Berindan-Neagoe; Samantha Perakis; Daniela Schwarzenbacher; Michael Stotz; Armin Gerger; Martin Pichler
Journal:  Int J Mol Sci       Date:  2016-04-15       Impact factor: 5.923

9.  Quantitative Assessment of the Polymorphisms in the HOTAIR lncRNA and Cancer Risk: A Meta-Analysis of 8 Case-Control Studies.

Authors:  Tian Tian; Chunjian Li; Jing Xiao; Yi Shen; Yihua Lu; Liying Jiang; Xun Zhuang; Minjie Chu
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

Review 10.  Regulatory Roles of Non-Coding RNAs in Colorectal Cancer.

Authors:  Jun Wang; Yong-Xi Song; Bin Ma; Jia-Jun Wang; Jing-Xu Sun; Xiao-Wan Chen; Jun-Hua Zhao; Yu-Chong Yang; Zhen-Ning Wang
Journal:  Int J Mol Sci       Date:  2015-08-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.